Tag Archives: OTC

Green light for proposed acquisition

The ACCC will not oppose GSK’s proposed acquisition of Pfizer’s consumer healthcare business in Australia. GSK and Pfizer supply prescription and over-the-counter medications including the well-known pain management products Panadol, Voltaren and Advil, as well as gastrointestinal and cold and flu products. The proposed acquisition combines only their over-the-counter businesses. …

Read More »

AFT gross profit up 32pc

AFT Pharmaceuticals’ gross profit for the year ended March 31, 2018 (FY2018) increased by 32 per cent to $34.2 million, according to its full-year audited financial results. Performance highlights include: Total income increased 16 per cent to $81.9 – comprising operating revenues of $80.1 million (previous corresponding period $69.2 million) and …

Read More »

Arrow and Apotex Australia to merge

Arrow Pharmaceuticals and Apotex have announced a proposed merger of their Australian and New Zealand generic pharmaceutical and OTC operations. The proposed merger, still subject to several conditions, including ACCC approval and due diligence, aims to create a sustainable platform for growth and development of the companies’ business interests in …

Read More »